[go: up one dir, main page]

MX2021008464A - Farmaco-enlazadores modificados con polietilenglicol para la farmacocinetica mejorada de conjugados de ligando-farmaco. - Google Patents

Farmaco-enlazadores modificados con polietilenglicol para la farmacocinetica mejorada de conjugados de ligando-farmaco.

Info

Publication number
MX2021008464A
MX2021008464A MX2021008464A MX2021008464A MX2021008464A MX 2021008464 A MX2021008464 A MX 2021008464A MX 2021008464 A MX2021008464 A MX 2021008464A MX 2021008464 A MX2021008464 A MX 2021008464A MX 2021008464 A MX2021008464 A MX 2021008464A
Authority
MX
Mexico
Prior art keywords
drug
ligand
linkers
pegylated
targeted cells
Prior art date
Application number
MX2021008464A
Other languages
English (en)
Inventor
Robert Lyon
Patrick Burke
Joshua Hunter
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52828847&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2021008464(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Publication of MX2021008464A publication Critical patent/MX2021008464A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A61K47/6885—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy the conjugate or the polymer being a starburst, a dendrimer, a cascade
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyethers (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención proporciona Conjugados de Ligando-Fármaco que comprenden una Unidad de PEG en una orientación paralela con respecto a la Unidad de Fármaco. La invención proporciona, inter alia, Conjugados de Ligando-Fármaco (LDCs), métodos para prepararlos y utilizarlos, y compuestos intermedios de los mismos. Los Conjugados de Ligando-Fármacos son estables en circulación, sin embargo son capaces de causar la muerte celular en células fijadas como objetivo o de inhibir la proliferación de células fijadas como objetivo una vez que su carga de fármaco es liberada en la cercanía o dentro de las células fijadas como objetivo. En modalidades principales, un LDC de la presente invención es representado por la estructura de la Fórmula I.
MX2021008464A 2013-10-15 2014-10-14 Farmaco-enlazadores modificados con polietilenglicol para la farmacocinetica mejorada de conjugados de ligando-farmaco. MX2021008464A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361891320P 2013-10-15 2013-10-15
US201461941904P 2014-02-19 2014-02-19
US201461947742P 2014-03-04 2014-03-04
US201461975318P 2014-04-04 2014-04-04
PCT/US2014/060477 WO2015057699A2 (en) 2013-10-15 2014-10-14 Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics

Publications (1)

Publication Number Publication Date
MX2021008464A true MX2021008464A (es) 2023-03-03

Family

ID=52828847

Family Applications (4)

Application Number Title Priority Date Filing Date
MX2021008464A MX2021008464A (es) 2013-10-15 2014-10-14 Farmaco-enlazadores modificados con polietilenglicol para la farmacocinetica mejorada de conjugados de ligando-farmaco.
MX2016004609A MX385458B (es) 2013-10-15 2014-10-14 Farmaco-enlazadores modificados con polietilenglicol para la farmacocinetica mejorada de conjugados de ligando-farmaco.
MX2021008463A MX2021008463A (es) 2013-10-15 2016-04-11 Farmaco-enlazadores modificados con polietilenglicol para la farmacocinetica mejorada de conjugados de ligando-farmaco.
MX2021008465A MX2021008465A (es) 2013-10-15 2016-04-11 Farmaco-enlazadores modificados con polietilenglicol para la farmacocinetica mejorada de conjugados de ligando-farmaco.

Family Applications After (3)

Application Number Title Priority Date Filing Date
MX2016004609A MX385458B (es) 2013-10-15 2014-10-14 Farmaco-enlazadores modificados con polietilenglicol para la farmacocinetica mejorada de conjugados de ligando-farmaco.
MX2021008463A MX2021008463A (es) 2013-10-15 2016-04-11 Farmaco-enlazadores modificados con polietilenglicol para la farmacocinetica mejorada de conjugados de ligando-farmaco.
MX2021008465A MX2021008465A (es) 2013-10-15 2016-04-11 Farmaco-enlazadores modificados con polietilenglicol para la farmacocinetica mejorada de conjugados de ligando-farmaco.

Country Status (23)

Country Link
US (3) US11103593B2 (es)
EP (2) EP3756663A1 (es)
JP (4) JP6747971B2 (es)
KR (4) KR102645430B1 (es)
CN (1) CN105764503A (es)
AU (3) AU2014337555C1 (es)
BR (1) BR112016007622A2 (es)
CA (2) CA2921707C (es)
CY (1) CY1123675T1 (es)
DK (1) DK3057585T3 (es)
EA (1) EA201690780A1 (es)
ES (1) ES2826398T3 (es)
HU (1) HUE051389T2 (es)
IL (4) IL293071A (es)
MX (4) MX2021008464A (es)
NZ (2) NZ758050A (es)
PL (1) PL3057585T3 (es)
PT (1) PT3057585T (es)
SG (3) SG10201806917PA (es)
SI (1) SI3057585T1 (es)
TW (4) TWI811726B (es)
WO (1) WO2015057699A2 (es)
ZA (1) ZA201601436B (es)

Families Citing this family (157)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021008464A (es) 2013-10-15 2023-03-03 Seattle Genetics Inc Farmaco-enlazadores modificados con polietilenglicol para la farmacocinetica mejorada de conjugados de ligando-farmaco.
KR101628872B1 (ko) 2014-05-28 2016-06-09 주식회사 레고켐 바이오사이언스 자가-희생 기를 포함하는 화합물
EP3218009B1 (en) * 2014-10-14 2021-04-07 Polytherics Limited Process for the conjugation of a peptide or protein with a reagent comprising a leaving group including a portion of peg
KR102513926B1 (ko) * 2014-10-24 2023-03-23 폴리테릭스 리미티드 접합체 및 접합 시약
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
EA201992756A3 (ru) * 2015-03-18 2020-06-30 Сиэтл Дженетикс, Инк. Антитела против cd48 и их конъюгаты
TWI618697B (zh) 2015-11-03 2018-03-21 財團法人工業技術研究院 化合物、連接子－藥物、及配體－藥物耦合體
KR102847350B1 (ko) * 2015-11-25 2025-08-19 주식회사 리가켐바이오사이언스 분지된 링커를 포함하는 항체-약물 접합체 및 이의 제조방법
SMT202400223T1 (it) 2015-11-25 2024-07-09 Ligachem Biosciences Inc Coniugati comprendenti gruppi autoimmolativi e metodi correlati ad essi
JP7120765B2 (ja) * 2015-11-25 2022-08-17 レゴケム バイオサイエンシズ， インク． ペプチド基を含む複合体及びそれに関連する方法
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
ES2919323T3 (es) * 2015-12-04 2022-07-26 Seagen Inc Conjugados de compuestos de tubulisina cuaternizados
WO2017161206A1 (en) * 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
CN109843919A (zh) * 2016-03-25 2019-06-04 西雅图基因公司 用于制备聚乙二醇化的药物-接头及其中间体的方法
MA45328A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Compositions acide nucléique-polypeptide et utilisations de celles-ci
WO2017178828A1 (en) * 2016-04-14 2017-10-19 Polytherics Limited Conjugates and conjugating reagents comprising a linker that includes at least two (-ch2-ch2-0-) units in a ring
CN109069665A (zh) 2016-05-10 2018-12-21 百时美施贵宝公司 具有增强的稳定性的微管溶素类似物的抗体-药物缀合物
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
JP7031934B2 (ja) 2016-05-11 2022-03-08 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックス
EP3455243B1 (en) 2016-05-11 2021-03-24 Cytiva BioProcess R&D AB Separation matrix
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
US11708390B2 (en) 2016-05-11 2023-07-25 Cytiva Bioprocess R&D Ab Method of storing a separation matrix
US11753438B2 (en) 2016-05-11 2023-09-12 Cytiva Bioprocess R&D Ab Method of cleaning and/or sanitizing a separation matrix
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
TWI851531B (zh) * 2016-08-09 2024-08-11 美商思進公司 具有改善之生理化學性質之具自我穩定連接子之藥物結合物
US12448411B2 (en) 2016-09-30 2025-10-21 Cytiva Bioprocess R&D Ab Separation method
RU2755899C2 (ru) 2016-10-11 2021-09-22 Байондис Б.В. Нелинейные саморасщепляющиеся линкеры и их конъюгаты
KR20240000650A (ko) 2016-10-19 2024-01-02 인벤라 인코포레이티드 항체 구조물
IL307357A (en) 2016-11-08 2023-11-01 Regeneron Pharma Steroids and their protein conjugates
TWI807423B (zh) * 2016-11-14 2023-07-01 醣基生醫股份有限公司 抗體藥物複合體
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
JP7244987B2 (ja) * 2016-12-14 2023-03-23 シージェン インコーポレイテッド 多剤抗体薬物コンジュゲート
CA3045857A1 (en) 2016-12-22 2018-06-28 Universita Degli Studi Magna Graecia Catanzaro A monoclonal antibody targeting a unique sialoglycosilated cancer-associated epitope of cd43
SG10202107429WA (en) 2017-01-06 2021-08-30 Avidity Biosciences Inc Nucleic acid-polypeptide compositions and methods of inducing exon skipping
WO2018128826A1 (en) * 2017-01-06 2018-07-12 Cidara Therapeutics, Inc. Compositions and methods for the treatment of bacterial infections
CN110430901B (zh) 2017-03-24 2024-08-16 西雅图基因公司 制备葡糖苷酸药物-接头及其中间体的方法
JP7664680B2 (ja) 2017-03-29 2025-04-18 リガケム バイオサイエンシズ， インク． ピロロベンゾジアゼピン二量体前駆体及びそのリガンド－リンカーコンジュゲート化合物
CN110475802B (zh) 2017-03-30 2022-03-08 日油株式会社 异双官能性单分散聚乙二醇以及使用该异双官能性单分散聚乙二醇的缀合物
US11931414B2 (en) 2017-04-27 2024-03-19 Seagen Inc. Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates
KR102722886B1 (ko) 2017-05-10 2024-10-29 사노피 신규한 펩티드 링커 및 크립토피신 콘쥬게이트, 이들의 제조 및 이들의 치료적 용도
KR20250008984A (ko) 2017-05-18 2025-01-16 리제너론 파마슈티칼스 인코포레이티드 사이클로덱스트린 단백질 약물 접합체
US11696958B2 (en) * 2017-05-23 2023-07-11 Byondis B.V. Dual conjugation process for preparing antibody-drug conjugates
US20210100912A1 (en) 2017-06-19 2021-04-08 Sichuan Baili Pharmaceutical Co. Ltd. Antibody-drug conjugate having acidic self-stabilization junction
KR102913213B1 (ko) 2017-06-23 2026-01-15 벨로스바이오 인코포레이티드 Ror1 항체 면역접합체
GB201711809D0 (en) 2017-07-21 2017-09-06 Governors Of The Univ Of Alberta Antisense oligonucleotide
WO2019051489A1 (en) 2017-09-11 2019-03-14 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE
WO2019051488A1 (en) 2017-09-11 2019-03-14 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE
TWI885539B (zh) 2017-09-29 2025-06-01 日商第一三共股份有限公司 抗體－吡咯并苯二氮呯衍生物複合體
CN111655268B (zh) 2017-10-04 2024-03-26 艾维迪提生物科学公司 核酸-多肽组合物及其用途
CN120789287A (zh) 2017-10-23 2025-10-17 马布林克生物科学公司 包含单分子量聚肌氨酸的配体-药物-缀合物
MX2020004691A (es) * 2017-11-07 2020-08-20 Regeneron Pharma Enlazadores hidrofilicos para conjugados anticuerpo-farmaco.
SG11202003995PA (en) * 2017-11-14 2020-05-28 Debiopharm Res & Manufacturing S A Ligand-drug-conjugates as substrates for selective cleavage by the exopeptidase activity of cathepsin b
SG11202004128TA (en) * 2017-11-22 2020-06-29 Seattle Genetics Inc Acid-mediated assay for analyzing ligand-drug conjugates
EP3717021A1 (en) 2017-11-27 2020-10-07 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
EP3720448A4 (en) 2017-12-06 2021-11-03 Avidity Biosciences, Inc. COMPOSITIONS AND METHODS OF TREATMENT OF MUSCLE ATROPHY AND MYOTONIC DYSTROPHY
EP3727463A1 (en) 2017-12-21 2020-10-28 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
MY210236A (en) 2018-01-08 2025-09-04 Regeneron Pharma Steroids and antibody-conjugates thereof
CA3093645A1 (en) 2018-03-13 2019-09-19 Nof Corporation Heterobifunctional compound having monodispersed polyethylene glycol in main chain and side chain
MX2020009842A (es) 2018-03-23 2020-10-15 Seattle Genetics Inc Uso de conjugados de anticuerpo-farmaco que comprenden agentes interruptores de tubulina para tratar tumor solido.
WO2019209811A1 (en) 2018-04-24 2019-10-31 Bristol-Myers Squibb Company Macrocyclic toll-like receptor 7 (tlr7) agonists
SG11202010443WA (en) 2018-05-09 2020-11-27 Legochem Biosciences Inc Compositions and methods related to anti-cd19 antibody drug conjugates
EP3790899A1 (en) 2018-05-09 2021-03-17 Regeneron Pharmaceuticals, Inc. Anti-msr1 antibodies and methods of use thereof
JP7653260B2 (ja) 2018-06-05 2025-03-28 キングス・カレッジ・ロンドン 消化管系へのペイロード送達のための、ｂｔｎｌ３／８を標的とする構築物
TWI851577B (zh) * 2018-06-07 2024-08-11 美商思進公司 喜樹鹼結合物
CN113365664A (zh) 2018-10-29 2021-09-07 梅尔莎纳医疗公司 具有含肽接头的半胱氨酸工程化的抗体-药物缀合物
WO2020123882A1 (en) * 2018-12-12 2020-06-18 The General Hospital Corporation Prodrugs with a tridentate self-immolative linker
EP3897734A4 (en) * 2018-12-21 2022-12-07 Seagen Inc. ADC COMPRISING MULTIPLEX THIOL LINKERS
IL319265A (en) 2018-12-21 2025-04-01 Avidity Biosciences Inc Anti-transferrin receptor antibodies and their uses
CN113795264A (zh) 2019-03-19 2021-12-14 瓦尔希伯伦私人肿瘤研究基金会 采用Omomyc和结合PD-1或CTLA-4的抗体治疗癌症的联合疗法
US12497615B2 (en) 2019-04-25 2025-12-16 Avidity Biosciences, Inc. Nucleic acid compositions and methods of multi-exon skipping
JP2022530482A (ja) * 2019-05-02 2022-06-29 レゴケム バイオサイエンシズ， インク． トリス構造を有するリンカーを含むリガンド―薬物複合体
WO2020236521A1 (en) * 2019-05-17 2020-11-26 The Regents Of The University Of California Traceless linker and methods of use thereof
KR20220010527A (ko) * 2019-05-20 2022-01-25 노파르티스 아게 친수성 기를 포함하는 링커를 갖는 항체 약물 콘쥬게이트
CA3142283A1 (en) 2019-06-06 2020-12-10 Avidity Biosciences, Inc. Nucleic acid-polypeptide compositions and uses thereof
WO2020247818A1 (en) 2019-06-06 2020-12-10 Avidity Biosciences, Inc. Una amidites and uses thereof
KR20210028544A (ko) 2019-09-04 2021-03-12 주식회사 레고켐 바이오사이언스 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도
AU2020348876A1 (en) 2019-09-19 2022-04-07 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
CN114929284A (zh) 2019-10-04 2022-08-19 西根公司 喜树碱肽缀合物
CA3163833A1 (en) 2020-01-09 2021-07-15 Timothy B. Lowinger Site specific antibody-drug conjugates with peptide-containing linkers
WO2021151984A1 (en) 2020-01-31 2021-08-05 Innate Pharma Treatment of cancer
TW202144572A (zh) 2020-03-19 2021-12-01 美商亞維代堤生物科學公司 治療臉肩胛肱骨肌肉失養症之組合物及方法
BR112022019137A2 (pt) 2020-03-27 2023-01-31 Avidity Biosciences Inc Composições e métodos de tratamento de distrofia muscular
CN116196435B (zh) 2020-04-02 2025-12-02 梅尔莎纳医疗公司 包含sting激动剂的抗体药物缀合物
BR112022020332A2 (pt) 2020-04-10 2022-12-13 Seagen Inc Composto conjugado anticorpo-droga, composição, método de tratamento de câncer e de um distúrbio autoimune
BR112022020124A2 (pt) * 2020-04-15 2022-11-29 Shenzhen Enduring Biotech Ltd Conjugado anticorpo-fármaco
CN116390770A (zh) * 2020-05-13 2023-07-04 思进股份有限公司 使用抗cd30抗体-药物缀合物的组合治疗癌症的方法
CN113941007B (zh) * 2020-07-16 2024-06-07 成都科岭源医药技术有限公司 一种串联的双药物链接组装单元及其应用
CA3200974A1 (en) 2020-11-08 2022-05-12 Seagen Inc. Combination therapy
CA3196198A1 (en) 2020-11-25 2022-06-02 Manel KRAIEM Treatment of cancer
CN117642185A (zh) 2020-12-23 2024-03-01 路德维希-马克西米利安慕尼黑大学 改进的cd30靶向抗体药物偶联物及其用途
AU2022208054A1 (en) 2021-01-15 2023-07-27 Seagen Inc. Immunomodulatory antibody-drug conjugates
US11510994B2 (en) * 2021-01-29 2022-11-29 EqIP, LLC Linkers for improving the stability of bioconjugates and the selectivity of payload release
WO2022170002A1 (en) 2021-02-03 2022-08-11 Seagen Inc. Immunostimulatory compounds and conjugates
WO2022182743A1 (en) * 2021-02-23 2022-09-01 Children's Medical Center Corporation Intercellular adhesion molecule 1 (icam1) antibody drug conjugate and uses thereof
JP2024511360A (ja) 2021-03-18 2024-03-13 シージェン インコーポレイテッド 生体活性化合物の内部移行複合体からの選択的薬物放出
AU2022238571A1 (en) 2021-03-18 2023-09-14 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
CA3212610A1 (en) * 2021-04-20 2022-10-27 Philip MOQUIST Modulation of antibody-dependent cellular cytotoxicity
IL308795A (en) 2021-05-28 2024-01-01 Seagen Inc Anthracycline antibody conjugates
CA3222015A1 (en) 2021-06-01 2022-12-08 Ajinomoto Co., Inc. Conjugates of antibody and functional substance or salts thereof, and compounds used in production of the same or salts thereof
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
WO2023000131A1 (zh) * 2021-07-19 2023-01-26 烟台迈百瑞国际生物医药股份有限公司 一种负载双毒素的抗体药物偶联物及其应用
CN113698468B (zh) * 2021-09-01 2022-10-11 浙江新码生物医药有限公司 人白细胞介素2-聚乙二醇偶联物及其应用
US20250281630A1 (en) 2021-09-03 2025-09-11 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention
CA3231330A1 (en) 2021-09-16 2023-03-23 Avidity Biosciences, Inc. Compositions and methods of treating facioscapulohumeral muscular dystrophy
KR20240100415A (ko) 2021-11-09 2024-07-01 투불리스 게엠베하 인(v) 및 캄프토테신 모이어티를 포함하는 접합체
AU2022385379A1 (en) 2021-11-09 2024-06-20 Forschungsverbund Berlin E.V. Conjugates comprising a phosphorus (v) and a drug moiety
EP4433096A1 (en) 2021-11-19 2024-09-25 Ardeagen Corporation Gpc3 binding agents, conjugates thereof and methods of using the same
WO2023122347A2 (en) 2021-12-23 2023-06-29 Mirecule, Inc. Compositions for delivery of polynucleotides
US20250099531A1 (en) * 2022-01-23 2025-03-27 Celagenex Research (India) Pvt. Ltd. Synergistic compositions for enhancing tfeb-mediated intracellular clearance
WO2023163536A1 (ko) * 2022-02-25 2023-08-31 앱티스 주식회사 신규 항체 약물 접합체
CN119278055A (zh) 2022-03-17 2025-01-07 思进公司 喜树碱缀合物
US12071621B2 (en) 2022-04-05 2024-08-27 Avidity Biosciences, Inc. Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping
US20260000782A1 (en) 2022-04-07 2026-01-01 Twinpig Biolab Inc. Itgb2-mediated drug delivery system
IL316062A (en) 2022-04-14 2024-11-01 Debiopharm Res & Manufacturing S A Ligand-drug conjugates with improved pharmacokinetic properties and drug release
CN116966314A (zh) 2022-04-29 2023-10-31 成都百利多特生物药业有限责任公司 一种包含亲水性糖结构的配体-药物偶联物
US20250255981A1 (en) 2022-05-06 2025-08-14 Seagen Inc. Immunomodulatory antibody-drug conjugates
CA3252208A1 (en) 2022-05-20 2023-11-23 Novartis Ag ANTIBODY-DRUG CONJUGATES
EP4532020A1 (en) 2022-05-25 2025-04-09 Innate Pharma Nectin-4 binding agents
EP4536290A1 (en) * 2022-06-08 2025-04-16 Angiex, Inc. Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same
CN117281900A (zh) * 2022-06-16 2023-12-26 亚飞（上海）生物医药科技有限公司 肿瘤微环境激活的抗ctla-4抗体的偶联体及其应用
JP2025523498A (ja) * 2022-06-21 2025-07-23 ワシントン ユニバーシティ Ｖｌａ４阻害剤及びその使用
US20250367307A1 (en) 2022-06-30 2025-12-04 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention
EP4558511A2 (en) 2022-07-21 2025-05-28 Firefly Bio, Inc. Glucocorticoid receptor agonists and conjugates thereof
WO2024026474A1 (en) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
IL318450A (en) 2022-08-03 2025-03-01 Seagen Inc Immunostimulatory ANTI-PD-L1-Drug conjugates
EP4321522A1 (en) 2022-08-12 2024-02-14 Seagen Inc. Cytotoxic compounds and conjugates thereof
PE20251401A1 (es) 2022-09-02 2025-05-22 Merck Sharp And Dohme Llc Inhibidores de topoisomerasa-1 derivados de exatecan composiciones farmaceuticas y sus usos
KR20250060207A (ko) 2022-09-09 2025-05-07 미릭스 파마 리미티드 Nmt 억제제를 포함하는 항체 약물 접합체 및 이의 용도
AU2023353057A1 (en) * 2022-09-30 2025-05-01 Extend Biosciences, Inc. Long-acting parathyroid hormone
KR20250089547A (ko) 2022-10-25 2025-06-18 펩토믹, 에스.엘. 암 치료를 위한 조합 요법
AU2023366166A1 (en) 2022-10-25 2025-05-01 Merck Sharp & Dohme Llc Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof
CN120303006A (zh) * 2022-11-01 2025-07-11 阿比蒂斯有限公司 包含Fc结合单元的化合物及使用其制备的结合物
US20240173426A1 (en) 2022-11-14 2024-05-30 Regeneron Pharmaceuticals, Inc. Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
WO2024108053A1 (en) 2022-11-17 2024-05-23 Sanofi Ceacam5 antibody-drug conjugates and methods of use thereof
WO2024129756A1 (en) 2022-12-13 2024-06-20 Seagen Inc. Site-specific engineered cysteine antibody drug conjugates
KR20250169306A (ko) * 2023-04-18 2025-12-02 아스트라제네카 아베 절단가능한 링커를 포함하는 접합체
TW202506691A (zh) 2023-04-20 2025-02-16 美商思進公司 Ｓｔｉｎｇ促效劑化合物及其結合物
WO2024231224A2 (en) * 2023-05-05 2024-11-14 BioNTech SE Antibody-drug conjugates employing novel linker-payload systems for enhanced targeting of cancer-associated antigens
CN118924912A (zh) * 2023-05-09 2024-11-12 诺灵生物医药科技(北京)有限公司 一种抗体偶联药物及其用途
WO2024240162A1 (en) 2023-05-23 2024-11-28 Shanghai Allygen Biologics Co., Ltd. Pd-l1 and trop-2 targeting conjugates comprising effector molecules and uses thereof
TW202513088A (zh) 2023-06-07 2025-04-01 瓦爾希伯倫私人腫瘤研究基金會 用於治療癌症的與ｍｅｋ抑制劑的組合療法
EP4473974A1 (en) 2023-06-07 2024-12-11 Peptomyc, S.L. Omomyc and kras inhibitors combination therapy for the treatment of cancer
WO2024251854A1 (en) 2023-06-07 2024-12-12 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Combination therapy with braf inhibitors for the treatment of cancer
US12491257B2 (en) 2023-06-27 2025-12-09 Avidity Biosciences, Inc. Compositions and methods of using PRKAG2-targeting antibody-oligonucleotide conjugates
WO2025003396A1 (en) * 2023-06-28 2025-01-02 Université De Tours Pegylated linkers and uses thereof
AU2024308906A1 (en) 2023-06-30 2026-02-05 Avidity Biosciences, Inc. Compositions and methods of using pln-targeting antibody-oligonucleotide conjugates
WO2025027529A1 (en) 2023-07-31 2025-02-06 Advesya Anti-il-1rap antibody drug conjugates and methods of use thereof
EP4509142A1 (en) 2023-08-16 2025-02-19 Ona Therapeutics S.L. Fgfr4 as target in cancer treatment
WO2025064424A1 (en) * 2023-09-18 2025-03-27 R.P. Scherer Technologies, Llc Tandem-cleavage linkers for antibody-drug conjugates and uses thereof
EP4534101A1 (en) 2023-10-02 2025-04-09 Eli Lilly and Company Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload
AR134171A1 (es) 2023-10-24 2025-12-10 Seagen Inc Compuestos quimioterapéuticos y métodos de uso
TW202530255A (zh) 2023-12-15 2025-08-01 法商亞維西亞有限公司 抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物
WO2025149947A1 (en) 2024-01-12 2025-07-17 Seagen Inc. Antibody-drug conjugates
WO2025196639A1 (en) 2024-03-21 2025-09-25 Seagen Inc. Cd25 antibodies, antibody-drug conjugates, and uses thereof
WO2025231037A1 (en) * 2024-04-30 2025-11-06 Solve Therapeutics, Inc. Conjugates of anti-ptk7 antibodies
CN120795217B (zh) * 2025-09-09 2025-12-09 内蒙古工业大学 一种用于催化co2转化的多相催化剂及其制备方法和应用

Family Cites Families (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2036891B (en) 1978-12-05 1983-05-05 Windsor Smith C Change speed gear
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
WO1987002671A1 (en) 1985-11-01 1987-05-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
IL106992A (en) 1988-02-11 1994-06-24 Bristol Myers Squibb Co Acylhydrazone derivatives of anthracycline and methods for their preparation
US5851527A (en) 1988-04-18 1998-12-22 Immunomedics, Inc. Method for antibody targeting of therapeutic agents
CA2006596C (en) 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US6569834B1 (en) 1992-12-03 2003-05-27 George R. Pettit Elucidation and synthesis of antineoplastic tetrapeptide w-aminoalkyl-amides
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
EP0731106B1 (en) 1993-10-01 2004-11-17 Teikoku Hormone Mfg. Co., Ltd. Dolastatin derivatives
US5605976A (en) 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
JP2763020B2 (ja) 1995-04-27 1998-06-11 日本電気株式会社 半導体パッケージ及び半導体装置
US5756593A (en) 1995-05-15 1998-05-26 Enzon, Inc. Method of preparing polyalkyene oxide carboxylic acids
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
WO1997023243A1 (en) 1995-12-22 1997-07-03 Bristol-Myers Squibb Company Branched hydrazone linkers
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
ATE365562T1 (de) 1996-05-03 2007-07-15 Immunomedics Inc Zielgerichtete kombinations-immuntherapie für krebs
US7011812B1 (en) 1996-05-03 2006-03-14 Immunomedics, Inc. Targeted combination immunotherapy of cancer and infectious diseases
ATE341344T1 (de) 1996-08-02 2006-10-15 Ortho Mcneil Pharm Inc Polypeptide mit einzelnem kovalent gebundenen n- terminalen wasserlöslichen polymer
US6261537B1 (en) 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
US6331289B1 (en) 1996-10-28 2001-12-18 Nycomed Imaging As Targeted diagnostic/therapeutic agents having more than one different vectors
US20040009166A1 (en) 1997-04-30 2004-01-15 Filpula David R. Single chain antigen-binding polypeptides for polymer conjugation
JP2002505574A (ja) 1997-04-30 2002-02-19 エンゾン，インコーポレイテッド ポリアルキレンオキシド修飾された単鎖ポリペプチド
GB2332539B (en) 1997-12-17 2003-04-23 Fujitsu Ltd Memory access methods and devices for use with random access memories
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US5965119A (en) 1997-12-30 1999-10-12 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
US7060479B2 (en) 1999-12-08 2006-06-13 Serono Genetics Institute, S.A. Full-length human cDNAs encoding potentially secreted proteins
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
US6214330B1 (en) 1998-07-13 2001-04-10 Enzon, Inc. Coumarin and related aromatic-based polymeric prodrugs
US6361774B1 (en) 1999-09-17 2002-03-26 Immunomedics, Inc. Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug
JP2000230000A (ja) * 1999-02-08 2000-08-22 Hokkaido Univ 一酸化窒素代謝物−ポリオキシアルキレン−ヘモグロビン結合体
WO2001062827A2 (en) 2000-02-22 2001-08-30 Shearwater Corporation N-maleimidyl polymer derivatives
US6777387B2 (en) 2000-03-31 2004-08-17 Enzon Pharmaceuticals, Inc. Terminally-branched polymeric linkers containing extension moieties and polymeric conjugates containing the same
AU2001272017A1 (en) 2000-06-20 2002-01-02 Immunomedics Inc. Targeted combination immunotherapy of cancer and infectious diseases
US7090843B1 (en) 2000-11-28 2006-08-15 Seattle Genetics, Inc. Recombinant anti-CD30 antibodies and uses thereof
JP4179771B2 (ja) 2001-06-25 2008-11-12 株式会社デンソー 自動車の乗員保護装置
WO2003026577A2 (en) 2001-09-24 2003-04-03 Seattle Genetics, Inc. P-amidobenzylethers in drug delivery agents
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
MXPA04004336A (es) 2001-11-07 2005-05-16 Nektar Therapeutics Al Corp Polimeros ramificados y sus conjugados.
WO2003070823A2 (en) 2002-02-20 2003-08-28 The General Hospital Corporation Conjugates comprising a biodegradable polymer and uses therefor
US7591994B2 (en) 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
GB0218518D0 (en) 2002-03-22 2002-09-18 Aventis Pharma Inc Human deubiquitinating protease gene on chromosome 7 and its murine ortholog
US20090068178A1 (en) 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
EP2353611B1 (en) 2002-07-31 2015-05-13 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
US7413738B2 (en) 2002-08-13 2008-08-19 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on biodegradable linkers
AU2003287605A1 (en) 2002-11-12 2004-06-03 Enzon Pharmaceuticals, Inc. Polymeric prodrugs of vancomycin
WO2004044223A2 (en) 2002-11-12 2004-05-27 Enzon Pharmaceuticals, Inc. Prodrugs of vancomycin with hydrolysis resistant polymer linkers
DE10254439A1 (de) 2002-11-21 2004-06-03 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Tubulysine, Herstellungsverfahren und Tubulysin-Mittel
US7888536B2 (en) 2004-02-13 2011-02-15 Quanta Biodesign, Ltd. Selective and specific preparation of discrete PEG compounds
US7332164B2 (en) 2003-03-21 2008-02-19 Enzon Pharmaceuticals, Inc. Heterobifunctional polymeric bioconjugates
JP5209204B2 (ja) 2003-04-13 2013-06-12 エンゾン ファーマスーティカルズ インコーポレイテッド ポリマーオリゴヌクレオチドプロドラッグ
EP2281577B1 (en) 2003-05-14 2016-11-16 ImmunoGen, Inc. Drug conjugate composition
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
PT2489364E (pt) 2003-11-06 2015-04-16 Seattle Genetics Inc Compostos de monometilvalina conjugados com anticorpos
CA2556752C (en) 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
EP1732607B1 (en) 2004-03-23 2019-05-15 Ascendis Pharma GmbH Polymeric prodrug with a self-immolative linker
CA2564076C (en) 2004-05-19 2014-02-18 Medarex, Inc. Chemical linkers and conjugates thereof
CA2586909A1 (en) 2004-11-12 2006-12-14 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the n terminus
US20070134243A1 (en) 2004-12-01 2007-06-14 Gazzard Lewis J Antibody drug conjugates and methods
US7947839B2 (en) 2004-12-01 2011-05-24 Genentech, Inc. Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use
NZ556317A (en) 2005-01-31 2011-01-28 Genentech Inc Anti-EphB2 antibodies and methods using same
JP4877225B2 (ja) 2005-02-18 2012-02-15 日油株式会社 ポリオキシアルキレン誘導体
EP2511299A1 (en) 2005-04-19 2012-10-17 Seattle Genetics, Inc. Humanized anti-CD70 binding agents and uses thereof
US8132476B2 (en) 2005-06-20 2012-03-13 Hy-Energy, Llc Method and apparatus for handling small quantities of fluids
WO2007008848A2 (en) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
WO2007011968A2 (en) * 2005-07-18 2007-01-25 Seattle Genetics, Inc. Beta-glucuronide-linker drug conjugates
US20110014151A1 (en) 2006-01-11 2011-01-20 Biotech Igg Ab Macromolecule conjugate
EP1813614B1 (en) 2006-01-25 2011-10-05 Sanofi Cytotoxic agents comprising new tomaymycin derivatives
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
WO2007103288A2 (en) 2006-03-02 2007-09-13 Seattle Genetics, Inc. Engineered antibody drug conjugates
US8257706B2 (en) 2006-08-25 2012-09-04 Seattle Genetics, Inc. CD30 binding agents and uses thereof
US8367065B2 (en) 2006-09-15 2013-02-05 Enzon Pharmaceuticals, Inc. Targeted polymeric prodrugs containing multifunctional linkers
CA2662981A1 (en) 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Targeted polymeric prodrugs containing multifunctional linkers
AU2007296190A1 (en) 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Lysine-based polymeric linkers
BRPI0716823A2 (pt) 2006-09-15 2015-05-26 Enzon Pharmaceuticals Inc Conjunto poliméricos contendo porções positivamente carregadas
NZ576751A (en) * 2006-11-10 2011-10-28 Covx Technologies Ireland Ltd Anti-angiogenic compounds
PT2099823E (pt) 2006-12-01 2014-12-22 Seattle Genetics Inc Agentes de ligação ao alvo variantes e suas utilizações
US7884869B2 (en) 2007-04-30 2011-02-08 Motorola Mobility, Inc. Assignment of pixel element exposure times in digital camera modules and mobile communication devices
CA2690943A1 (en) 2007-06-25 2008-12-31 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
TW200922624A (en) 2007-07-11 2009-06-01 Enzon Pharmaceuticals Inc Polymeric drug delivery system containing a multi-substituted aromatic moiety
JP2010533233A (ja) 2007-07-11 2010-10-21 エンゾン ファーマシューティカルズ，インコーポレーテッド 芳香族アリル酸を含むポリマー性薬剤送達システム
US20110263650A1 (en) 2007-07-20 2011-10-27 Helmholtz-Zentrum Für Infektions-Forschung Gmbh Tubulysin D Analogues
AU2007357885A1 (en) 2007-08-20 2009-02-26 Enzon Pharmaceuticals, Inc. Polymeric linkers containing pyridyl disulfide moieties
PT2211904T (pt) 2007-10-19 2016-11-02 Seattle Genetics Inc Agentes de ligação a cd19 e seus usos
PL2265283T3 (pl) 2008-03-18 2015-03-31 Seattle Genetics Inc Koniugaty aurystatyny lek łącznik
EP2174947A1 (en) 2008-09-25 2010-04-14 Universität des Saarlandes Bioactive pre-tubulysins and use thereof
CN102215688A (zh) 2008-10-21 2011-10-12 安龙制药公司 用7-乙基-10-羟基喜树碱的多臂聚合物对神经母细胞瘤的治疗
JP5823874B2 (ja) 2009-01-09 2015-11-25 シアトル ジェネティクス，インコーポレーテッド 抗ＣＤ３０ｖｃ−ＰＡＢ−ＭＭＡＥ抗体−薬物コンジュゲートのウィークリー投与計画
AU2010210646B2 (en) 2009-02-05 2015-10-29 Immunogen, Inc. Novel benzodiazepine derivatives
FR2949469A1 (fr) 2009-08-25 2011-03-04 Sanofi Aventis Derives anticancereux, leur preparation et leur application en therapeutique
EP2480230A4 (en) 2009-09-24 2015-06-10 Seattle Genetics Inc DR5 Ligand-HEILMITTELKONJUGATE
EP2486023A4 (en) 2009-10-06 2014-05-07 Immunogen Inc EFFICIENT CONJUGATES AND HYDROPHILIC BINDER
WO2011072240A1 (en) 2009-12-10 2011-06-16 Cedars-Sinai Medical Center Drug delivery of temozolomide for systemic based treatment of cancer
TWI504410B (zh) 2010-02-08 2015-10-21 Agensys Inc 結合至１６１ｐ２ｆ１０ｂ蛋白之抗體藥物結合物（ａｄｃ）
US9725500B2 (en) 2010-03-02 2017-08-08 Seattle Genetics, Inc. Methods for screening antibodies
WO2011120053A1 (en) 2010-03-26 2011-09-29 Mersana Therapeutics, Inc. Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof
NZ602933A (en) 2010-04-15 2014-09-26 Seattle Genetics Inc Pyrrolobenzodiazepines used to treat proliferative diseases
MA34277B1 (fr) 2010-04-15 2013-06-01 Spirogen Developments Sarl Pyrrolobenzodiazépines et conjugués de celles-ci
JP5870400B2 (ja) 2010-04-15 2016-03-01 シアトル ジェネティクス，インコーポレーテッド 標的化ピロロベンゾジアゼピンコンジュゲート
WO2011130599A1 (en) 2010-04-16 2011-10-20 Enzon Pharmaceuticals, Inc. Polymeric conjugates of adenine nucleoside analogs
EP2409983A1 (en) 2010-07-19 2012-01-25 Leibniz-Institut für Pflanzenbiochemie (IPB) Tubulysin analogues
SI3461847T1 (sl) 2010-12-06 2021-03-31 Seagen Inc. Humanizirana protitelesa proti LIV-1 in njihova uporaba pri zdravljenju raka
MY183977A (en) 2011-02-15 2021-03-17 Immunogen Inc Cytotoxic benzodiazepine derivatives
PL2678037T3 (pl) * 2011-02-25 2015-05-29 Lonza Ag Rozgałęziony łącznik do koniugatów białko-lek.
EP2714684B1 (en) 2011-05-27 2018-09-05 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
US20130052130A1 (en) 2011-08-30 2013-02-28 University Of Washington Branched Discreet PEG Constructs
WO2013041606A1 (en) 2011-09-20 2013-03-28 Spirogen Sàrl Pyrrolobenzodiazepines as unsymmetrical dimeric pbd compounds for inclusion in targeted conjugates
AU2012322613B2 (en) 2011-10-14 2016-04-21 Medimmune Limited Pyrrolobenzodiazepines and targeted conjugates
JP6393617B2 (ja) 2011-10-14 2018-09-19 シアトル ジェネティクス，インコーポレーテッド ピロロベンゾジアゼピンおよび標的コンジュゲート
EP2751111B1 (en) 2011-10-14 2017-04-26 MedImmune Limited Asymmetrical bis-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one) derivatives for the treatment of proliferative or autoimmune diseases
EP2814509B1 (en) 2012-02-17 2018-05-16 Seattle Genetics, Inc. Antibodies to integrin v 6 and use of same to treat cancer
US20130225789A1 (en) 2012-02-29 2013-08-29 Yi Sun Polyethylene Glycol Having Hetero Multiple Functional Groups
CA2873112A1 (en) 2012-05-11 2013-11-14 Alexander Krantz Site-specific labeling and targeted delivery of proteins for the treatment of cancer
US9504756B2 (en) * 2012-05-15 2016-11-29 Seattle Genetics, Inc. Self-stabilizing linker conjugates
CN104662000B (zh) 2012-05-15 2018-08-17 索伦托医疗有限公司 药物偶联物及其偶联方法和用途
HK1207388A1 (en) 2012-05-15 2016-01-29 Seattle Genetics, Inc. Self-stabilizing linker conjugates
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
US9650331B2 (en) 2012-06-18 2017-05-16 Polytherics Limited Conjugation reagents
WO2014061277A1 (ja) 2012-10-19 2014-04-24 第一三共株式会社 親水性構造を含むリンカーで結合させた抗体－薬物コンジュゲート
JP6328648B2 (ja) 2012-10-24 2018-05-23 ポリセリックス・リミテッド 新規薬物−タンパク質コンジュゲート
MX2021008464A (es) 2013-10-15 2023-03-03 Seattle Genetics Inc Farmaco-enlazadores modificados con polietilenglicol para la farmacocinetica mejorada de conjugados de ligando-farmaco.
GB201416960D0 (en) * 2014-09-25 2014-11-12 Antikor Biopharma Ltd Biological materials and uses thereof

Also Published As

Publication number Publication date
WO2015057699A3 (en) 2015-09-24
SG10201806917PA (en) 2018-09-27
JP6747971B2 (ja) 2020-08-26
KR20240034882A (ko) 2024-03-14
KR20220018616A (ko) 2022-02-15
DK3057585T3 (da) 2020-10-19
EA201690780A1 (ru) 2016-08-31
PL3057585T3 (pl) 2020-12-28
US20160310612A1 (en) 2016-10-27
TW202214300A (zh) 2022-04-16
KR20230082060A (ko) 2023-06-08
NZ758049A (en) 2024-03-22
CA2921707A1 (en) 2015-04-23
JP7330309B2 (ja) 2023-08-21
KR102538993B1 (ko) 2023-06-02
SG10201707274WA (en) 2017-10-30
AU2014337555A1 (en) 2016-03-03
JP2016534990A (ja) 2016-11-10
CA2921707C (en) 2023-03-28
AU2014337555C1 (en) 2021-01-28
TWI736047B (zh) 2021-08-11
EP3756663A1 (en) 2020-12-30
US20240325561A1 (en) 2024-10-03
AU2022204701A1 (en) 2022-07-21
MX385458B (es) 2025-03-18
AU2020202853A1 (en) 2020-05-21
EP3057585B1 (en) 2020-07-22
TW202417050A (zh) 2024-05-01
NZ758050A (en) 2024-03-22
BR112016007622A2 (pt) 2018-01-23
KR102645430B1 (ko) 2024-03-11
NZ758047A (en) 2024-03-22
IL275830A (en) 2020-08-31
CY1123675T1 (el) 2021-05-05
JP2023116821A (ja) 2023-08-22
PT3057585T (pt) 2020-10-21
EP3057585A4 (en) 2017-09-13
JP2022043354A (ja) 2022-03-15
JP2020012002A (ja) 2020-01-23
EP3057585A2 (en) 2016-08-24
TWI811726B (zh) 2023-08-11
ZA201601436B (en) 2020-07-29
AU2020202853B2 (en) 2022-04-07
AU2014337555B2 (en) 2020-05-21
SI3057585T1 (sl) 2020-12-31
IL278198B (en) 2022-03-01
TWI681778B (zh) 2020-01-11
IL275830B (en) 2022-06-01
IL244034A0 (en) 2016-04-21
IL278198A (en) 2020-11-30
MX2021008463A (es) 2021-08-19
KR20160062137A (ko) 2016-06-01
CA3187392A1 (en) 2015-04-23
HUE051389T2 (hu) 2021-03-01
US11103593B2 (en) 2021-08-31
US20220072146A1 (en) 2022-03-10
WO2015057699A2 (en) 2015-04-23
MX2021008465A (es) 2021-08-19
KR102356814B1 (ko) 2022-01-28
NZ717668A (en) 2024-03-22
TW202010517A (zh) 2020-03-16
MX2016004609A (es) 2016-08-01
ES2826398T3 (es) 2021-05-18
TW201515662A (zh) 2015-05-01
IL293071A (en) 2022-07-01
SG11201600954XA (en) 2016-03-30
CN105764503A (zh) 2016-07-13

Similar Documents

Publication Publication Date Title
MX2021008464A (es) Farmaco-enlazadores modificados con polietilenglicol para la farmacocinetica mejorada de conjugados de ligando-farmaco.
ZA202004099B (en) Methylene carbamate linkers for use with targeted-drug conjugates
CL2015000829A1 (es) Inhibidores de histona desmetilasas
ZA201505813B (en) Biologically active molecules, conjugates thereof, and therapeutic uses
MX2016008448A (es) Conjugados de var2csa-farmaco.
CY1119577T1 (el) Συν-αγωνιστες υποδοχεα γλυκαγονης/glp-1
AR093377A1 (es) Anticuerpos anti-notch y conjugados de anticuerpo-farmaco
MX2013015168A (es) Co-agonista del receptor de glucagon/glp-1.
MX2017017079A (es) Sistema de administracion dirigida de principio activo celular.
GB201203442D0 (en) Immunotherapeutic molecules and uses
DK2925272T3 (da) Lægemiddelopbevarings-, udleverings- og administrationssystem
MY177989A (en) Lna oligonucleotide carbohydrate conjugates
MX2020002867A (es) Inhibidores de glucosilceramida sintasa.
BR112014032990A2 (pt) seringa
CR20150236A (es) Métodos para el tratamiento del síndrome de alport
MX356097B (es) Proceso para la preparacion de nanoparticulas terapeuticas.
EP2899199A4 (en) Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate
EA201491447A1 (ru) Ендиины, их конъюгаты и способы их получения и применения
MX2018001511A (es) Polimeros furtivos desordenados de forma intrinseca codificados geneticamente para suministro y metodos para usar los mismos.
UA115135C2 (uk) Катіонні полімери на основі глікогену
EA201491702A1 (ru) Оптимизированные терапевтические агенты для подкожного введения
MX350159B (es) Inyecciones mejoradas.
Wenping et al. People-to-People Cooperation: Foundation to Consolidate China-Africa Relationsr
EP4212181A3 (en) Methylene carbamate linkers for use with targeted-drug conjugates
唐志强 The effect of microRNA-21-siRNA-lentivirus on biological behaviors in human hepatic cancer cell line hepG2